For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 0 | |||
| Research and development | 11,341,000 | |||
| General and administrative | 13,382,000 | |||
| Total operating expenses | 24,723,000 | |||
| Interest income | 105,000 | |||
| Interest expense, related party | 843,000 | |||
| Change in fair value of warrants | 0 | |||
| Foreign exchange loss | -7,000 | |||
| Total other (expenses) income | -745,000 | |||
| Net loss and comprehensive loss | -25,468,000 | |||
| Basic EPS | -10.41 | |||
| Diluted EPS | -10.41 | |||
| Basic Average Shares | 2,447,353 | |||
| Diluted Average Shares | 2,447,353 | |||
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)